US6423489B1
Expired / Lapsed
US
⏱️ 0.0 years remaining
Compositions and methods for treatment of Hepatitis C virus-associated diseases
Assignee: Ionis Pharmaceuticals Inc
•
Filing: 1995-05-30
•
Granted: 2002-07-23
•
Expires: 2015-05-30
Abstract
Abstract Antisense oligonucleotides are provided which are complementary to and hybridizable with at least a portion of HCV RNA and which are capable of inhibiting the function of the HCV RNA. These oligonucleotides can be administered to inhibit the activity of Hepatitis C virus in vivo or in vitro. These compounds can be used either prophylactically or therapeutically to reduce the severity of diseases associated with Hepatitis C virus, and for diagnosis and detection of HCV and HCV-associated diseases. Methods of using these compounds are also disclosed.
Inventors
- 👤 Kevin P. Anderson
- 👤 Ronnie C. Hanecak
- 👤 Kazuya Hoshiko
- 👤 Chikateru Nozaki
- 👤 Tsukasa Nishihara
- 👤 Hiroshi Nakatake
- 👤 Fukusaburo Hamada
- 👤 Tatsuo Eto
- 👤 Shinichi Furukawa
- 👤 Shoji Furusako
- 👤 Thomas W. Bruice
- 👤 Walter F. Lima
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-31 00:13
CPC Classifications
C; C12; C12N; C12N15/00; C12N15/09; C12N15/11; C12N15/113; C12N15/1131; C07; C07H; C07H21/00; C07K; C07K14/00; C07K14/005; C12Q; C12Q1/00; C12Q1/70; C12Q1/701; C12Q1/706; C12Q1/707; C12N2310/00; C12N2310/30; C12N2310/31; C12N2310/315; C12N2310/33; C12N2310/35; C12N2310/352; C12N2310/3521; C12N2310/3527; C12N2770/00; C12N2770/00011; C12N2770/24011; C12N2770/24211; C12N2770/24222
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
134 words
An oligonucleotide 5-50 nucleotides in length which is complementary to at least a portion of a 5′ end untranslated region, a polyprotein translation initiation codon region or core protein coding region of an HCV genomic or messenger RNA, said oligonucleotide inhibiting the function of said RNA and selected from the group consisting of SEQ ID NO: 20, SEQ ID NO: 33, SEQ ID NO: 42, SEQ ID NO: 72, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 73, SEQ ID NO: 85, SEQ ID NO: 86, SEQ ID NO: 91, SEQ ID NO: 99 SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, and SEQ ID NO: 107.
Claim 2
Dependent Claim
134 words
An oligonucleotide 5-50 nucleotides in length which is complementary to at least a portion of a 5′ end untranslated region, a polyprotein translation initiation codon region or core protein coding region of an HCV genomic or messenger RNA, said oligonucleotide inhibiting the function of said RNA and selected from the group consisting of SEQ ID NO: 20, SEQ ID NO: 33, SEQ ID NO: 42, SEQ ID NO: 72, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 78, SEQ ID NO: 73, SEQ ID NO: 85, SEQ ID NO: 86, SEQ ID NO: 91, SEQ ID NO: 99 SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 106, and SEQ ID NO: 107.
Claim 3
Dependent Claim
13 words
The oligonucleotide of claim 1 which comprises at least one modified intersugar linkage.
Claim 4
Dependent Claim
16 words
The oligonucleotide of claim 2 wherein the intersugar linkage is a phosphorothioate, PNA or methylene(methylimino) linkage.
Claim 5
Dependent Claim
21 words
The oligonucleotide of claim 1 which comprises an —O-alkyl or fluoro modification at the 2′-position of at least one sugar moiety.
Claim 6
Dependent Claim
31 words
The oligonucieotide of claim 1 having a universal base at a position which is complementary to a nucleotide in the HCV RNA which is variable among strains of Hepatitis C virus.
Claim 7
Dependent Claim
11 words
The oligonucleotide of claim 5 wherein the universal base is inosine.
Claim 8
Dependent Claim
40 words
A method for inhibiting the activity of a Hepatitis C virus comprising contacting the virus or cells infected with the virus with an effective amount of an oligonucleotide of claim 1 so that activity of Hepatitis C virus is inhibited.
References Cited (Backward Citations)
US5034506A
Cited
US5194428A
Cited
US4806463A
Cited
US5276019A
Cited
US5264423A
Cited
US5714596A
Cited
US5004810A
Cited
EP0388232A1
Cited
US5166195A
Cited
WO1992019743A2
Cited
US5610054A
Cited
CA2104649A1
Cited
WO1994008002A2
Cited
US5922857A
Cited
WO1994024864A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2005-07-22 | 2006-01-21 | 2006-07-23 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2009-07-22 | 2010-01-21 | 2010-07-23 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2013-07-22 | 2014-01-21 | 2014-07-23 | $7700.00 | Window Closed / Lapsed |